Drugs targeting Alzheimer's disease: Some things old and some things new

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 3, 2003, Pages 897-904

  Michaelis, Mary L ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA SECRETASE; CAPTOPRIL; CHELATING AGENT; CHOLESTEROL; CHOLINESTERASE INHIBITOR; CLIOQUINOL; CONGO RED; CYANOCOBALAMIN; DONEPEZIL; DOXORUBICIN; GALANTAMINE; GAMMA SECRETASE; GLUTAMATE RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOTRANSFERASE; PRESENILIN 1; PRESENILIN 2; PROLINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ATTENTION; CHOLESTEROL TRANSPORT; CHOLINERGIC ACTIVITY; COGNITION; DEMENTIA; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GENE DELETION; GENE MUTATION; HUMAN; IMMUNOTHERAPY; MICROTUBULE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SENILE PLAQUE; SIGNAL TRANSDUCTION; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ENDOPEPTIDASES; CENTRAL NERVOUS SYSTEM; ENDOPEPTIDASES; HUMANS; NEURODEGENERATIVE DISEASES; NEUROFIBRILS;

EID: 0037369507     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.035840     Document Type: Review

References (50)

1. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med 6:916-919.
2. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, and Hof PR (2000) τ protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 33:95-130.
3. Busciglio J, Lorenzo A, Yeh J, and Yankner BA (1995) β-amyloid fibrils induce τ phosphorylation and loss of microtubule binding. Neuron 14:879-888.
4. Cao X and Sudhof TC (2001) A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science (Wash DC) 293:115-120.
5. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676.
6. Davies TG, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Hardeastle IR, et al. (2002) Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol 9:745-749.
7. Delacourte A and Buee L (2000) Tau pathology: a marker of neurodegenerative disorders. Curr Opin Neurol 13:371-376.
8. DeMattos RB, Bales KR, Cummins DJ, Paul SM, and Holtzman DM (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (Wash DC) 295:2264-2267.
9. Dhavan R and Tsai L (2001) A decade of Cdk5. Nature Rev 2:749-759.
10. Engler H, Nordberg A, Blomqvist G, Bergstrom M, Estrada S, Barletta J, Sandell J, Antoni G, Langstrom B, Klunk W, et al. (2002) First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. Neurobiol Aging 23, 51:5249.
11. Ferris SH, Schmidt F, Doody R, Moebius HJ, Stoeffler A, and Reisberg B (2001) Long-term treatment with the NMDA antagonist, memantine: results of a 24-week, open-label extension study in advanced AD. Am Coll Neuropsychopharm.
12. Glenner GG and Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885-890.
13. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, and Yankner BA (1998) Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat Med 4:827-831.
14. Hardy J (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20:154-159.
15. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, and Tang J (2000) Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science (Wash DC) 290:150-153.
16. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, and Schmidt SD (2000) A β peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature (Lond) 408:979-982.
17. Kawahara M, Kuroda Y, Arispe N, and Rojas E (2000) Alzheimer's β-amypod, human islet amylin and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem 275:14077-14083.
18. Kinoshita A, Whelan CM, Smith CJ, Mikhailenko I, Rebeck WG, Strickland DK, and Hyman BT (2001) Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein, receptor-related Protein and the amyloid precursor protein: role of the intracellular adapter protein Fe65. J Neurosci 21:8354-8361.
19. Kopan R and Goate A (2000) A common enzyme connects Notch signaling and Alzheimer's disease. Genes 14:2799-2806.
20. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, and Ashe KH (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22:6331-6335.
21. Lau LF, Schachter JB, Seymour PA, and Sanner MA (2002) τ protein phosphorylation as a therapeutic target in Alzheimer's disease. Curr Top Med Chem 2:395-415.
22. Lee VM, Goedert M, and Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121-1159.
23. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (Wash DC) 293:1487-1491.
24. Li G, Faibushevich A, Sung OY, Turunen B, Georg G. Michaelis ML, Dobrowsky RT (2003) Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases β-amyloid toxicity in cortical neurons. J Neurochem 84:1-16.
25. Maelicke A, Schrattenholz A, and Samochocki M (2000) Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 113:199-206.
26. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, and Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245-4249.
27. McGeer PL and McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer's and other neurodegenerative diseases. Brain Res Rev 21:195-218.
28. Michaelis ML, Dobrowsky RT, and Li G (2002) τ neurofibrillary pathology and microtubule stability. J Mol Neurosci 19:289-293.
29. Michaelis ML, Ranciat N, Chen Y, Bechtel M, Ragan R, Hepperle M, Liu Y, and Georg G (1998) Protection against β-amyloid toxicity in primary neurons by paclitaxel [Taxol]. J Neurochem 70:1623-1627.
30. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al. (2000) Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (Lond) 408:982-985.
31. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, et al. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature (Land) 417:254-259.
32. Petersen RC (2000) Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 15:93-101.
33. Petit A, Bihel F, Alves da Costa C, Pourquie O, Cheeler F, and Kraus JL (2001) New protease inhibitors prevent gamma-secretase-mediated production of Aβ40/42 without affecting Notch cleavage. Nat Cell Biol 3:507-511.
34. Poirier J (2000) Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann NY Acad Sci 924:81-90.
35. Rapoport M, Dawson HN, Binder LI, Vitek MP, and Ferreira A (2002) τ is essential to β-amyloid-induced neurotoxicity. Proc Natl Acad Sci 99:6364-6369.
36. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, and Duff KE (2001) A cholesterol-lowering drug reduces β-amyoid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8:890-899.
37. Roberson M and Harrell LE (1997) Cholinergic activity and amyloid precursor protein metabolism. Brain Res Re 25:50-69.
38. Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, Teplow DB, and Haass C (2001) Presenilin-dependent γ-secretase processing of β-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO (Eur Mol Biol Organ) J 2:835-841.
39. Sausville EA (2002) Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 8:S32-7.
40. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. (1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (Lond) 400:173-177.
41. Selkoe DJ (2001) Alzheimer's disease: genes, proteins and therapy. Physiol Rev 81:741-766.
42. Shen J, Bronson RT, Chen DF, Xia W, and Selkoe DJ (1997) Skeletal and CNS defects in presenilin-1-deficient mice. Cell 89:629-639.
43. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, et al. (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature (Lond) 402:537-540.
44. Vassar R and Citron M (2000) Aβ-generating enzymes: recent advances in β- and γ-secretase research. Neuron 27:419-422.
45. Velentza AV, Schumacher AM, and Watterson DM (2002) Death associated protein kinase as a potential therapeutic target. Expert Opin Ther Targets 6:497-506.
46. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, and Teplow DB (1999) Amyloid β-protein fibrillogenesis: structure and biological activity of protofibrillar intermediates. J Biol Chem 274:25945-25952.
47. Watterson DM, Haiech J, and Van Eldik LJ (2002) Discovery of new chemical classes of synthetic ligands that suppress neuroinflammatory responses. J Mol Neurosci 19:89-93.
48. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, et al. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature (Lond) 414:212-216.
49. Wilcock G and Truyen L (2002) Long-term safety, tolerability and efficacy of galantamine: Results from a 36-month analysis of extension study data. Neurobiol Aging 23, 51:5119.
50. Wolfe MS (2001) γ-Secretase inhibitors as molecular probes of presenilin function. J Mol Neurosci 17:199-204.